Home » Stocks » Perrigo

Perrigo Company PLC (PRGO)

Stock Price: $45.62 USD 0.14 (0.31%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Pre-market: $46.02 +0.40 (0.88%) Oct 26, 8:00 AM

Stock Price Chart

Key Info

Market Cap 6.23B
Revenue (ttm) 5.07B
Net Income (ttm) 240.20M
Shares Out 136.48M
EPS (ttm) 1.75
PE Ratio 26.07
Forward PE 10.53
Dividend $0.90
Dividend Yield 1.97%

Stock Quote

Trading Day Oct 23, 2020
Last Price $45.62
Previous Close $45.48
Change ($) 0.14
Change (%) 0.31%
Day's Open 45.70
Day's Range 45.27 - 45.87
Day's Volume 431,827
52-Week Range 40.01 - 63.86

More Stats

Market Cap 6.23B
Enterprise Value 8.91B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date Aug 27, 2020
Shares Outstanding 136.48M
Float 136.21M
EPS (basic) 1.76
EPS (diluted) 1.75
FCF / Share 4.03
Dividend $0.90
Dividend Yield 1.97%
Earnings Yield 3.84%
FCF Yield 8.82%
Payout Ratio 49.40%
Shares Short 3.40M
Short Ratio 4.13
Short % of Float 2.50%
Beta 1.16
PE Ratio 26.07
Forward PE 10.53
P/FCF Ratio 11.34
PS Ratio 1.23
PB Ratio 1.05
Revenue 5.07B
Operating Income 310.60M
Net Income 240.20M
Free Cash Flow 549.10M
Net Cash -2.69B
Net Cash / Share -19.68
Gross Margin 34.95%
Operating Margin 6.12%
Profit Margin 4.70%
FCF Margin 10.82%
ROA 2.66%
ROE 4.13%
ROIC 6.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 4
Overweight 0
Hold 6
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(25.21% upside)
Current: $45.62
Target: 57.12
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth2.23%-4.34%-6.33%24.92%8%10.57%11.55%15.18%21.46%-
Gross Profit1,7731,8321,9802,0521,6441,4521,2801,096945746
Operating Income205237598-2,000673571679569490336
Net Income146131120-4,013136233442402339224
Shares Outstanding13613814214313911593.9093.2092.3091.40
Earnings Per Share1.070.950.84-28.010.972.014.684.273.632.41
EPS Growth12.63%13.1%---51.74%-57.05%9.6%17.63%50.62%-
Dividend Per Share0.820.760.640.580.460.390.350.310.270.24
Dividend Growth7.89%18.75%10.34%26.09%17.95%11.43%12.9%13.55%12.81%-
Operating Cash Flow388593699655855633554513374332
Capital Expenditures-138-103-88.60-106-137-172-104-110-99.40-57.82
Free Cash Flow250490610549718461450404275275
Cash & Equivalents354551679622786800780603310510
Total Debt3,3693,2423,3415,7975,4003,2071,9741,3698931,344
Net Cash / Debt-3,015-2,691-2,663-5,175-4,615-2,407-1,194-767-583-834
Book Value5,8045,6686,1715,95810,6998,6932,3331,8531,5311,094
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Perrigo Company PLC
Country Ireland
Employees 11,200
CEO Murray S. Kessler

Stock Information

Ticker Symbol PRGO
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: PRGO
IPO Date December 16, 1991


Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid, 24HR, Good Sense, Zephrex D, ScarAway, Plackers, and Rembrandt. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands and consumer focused products through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.